NapiGen
Wilmington, US · Founded 2016 · 19 employees on LinkedIn · 7 known investors
Find your way into NapiGen
Napigen is a biotechnology company developing genome editing technology targeting the mitochondrial and chloroplast genomes.
Investors · 7
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$7.8M disclosed across 1 round · 2022
- $7.8Mseed fundingJul 2022 · 3 sources
Grantham Foundation (lead), RA Capital Management (lead), Breakout Labs/Thiel Foundation, Marsbio, Thrive SVG Ventures, United Mitochondrial Disease Foundation
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 5
by search overlapCompanies competing with NapiGen for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $225K |
| Department of Agriculture (USDA) | Phase I | 2020 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does NapiGen do?
- Napigen is a biotechnology company developing genome editing technology targeting the mitochondrial and chloroplast genomes.
- Who are NapiGen's investors?
- NapiGen's investors include RA Capital, The Innovation Space, Grantham Foundation, MarsBio.
- How much funding has NapiGen raised?
- NapiGen has disclosed $7.8M raised across 1 round.
- Where is NapiGen headquartered?
- NapiGen is headquartered in Wilmington, US.







